Consequently, the ERK1/2 pathway is a major target for drug development, and inhibitors of RAF and MEK are approved for treatment of melanoma, while ERK1/2 inhibitors are undergoing clinical trials; however, patients often relapse with drug-resistant tumours (7,8). Here, MAPK3 is linked to neoplasm.